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providers in better understanding the needs of the caregivers, thereby, ensuring 
optimal outcomes for their patient.  
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MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE USING EQ-5D IN 
PATIENTS WITH STROKE IN INDIA  
Marfatia S, Munshi S, Patel M 
pharmEDGE, Mumbai, India  
OBJECTIVES: To assess the impact of stroke on patient’s health related quality of 
life (HRQOL) using EQ-5D. METHODS: A convenient sample of 300 patients were 
recruited from six medical centers across three cities (Mumbai, Bangalore, and 
Delhi) in India. Patients older than 18 years diagnosed with stroke between June 
2011 to June 2012 who were receiving therapy for stroke were included in the 
study. Data on patients' socio-demographics, diagnosis, relevant clinical 
complications, were collected using a paper-based case report form. Patients 
were asked to rate their overall health using the EQ-VAS scale and data on the 
five dimensions of quality of life was collected using the EQ-5D questionnaire 
that was administered by trained interviewers. Translated and validated 
versions of the EQ-5D and EQ-VAS scales for five Indian languages were used in 
the study. RESULTS: The mean age of patients in the study was 58 (SD 14.45) and 
majority (70%) of the patients were males. Of the 300 patients, 60% had ischemic 
stroke. The mean EQ-VAS score was 66 (SD 23.09). Age and socioeconomic status 
were significant predictors (p<0.05, p<0.001 respectively) of EQ-VAS score. 
However, these variables were negatively correlated with the EQ-VAS score 
indicating that patients who were older and from an upper socioeconomic strata 
rated their overall health to be lower. Additionally, the frequency of problems 
was higher among older patients on mobility and usual care domains of the EQ-
5D scale than younger patients. CONCLUSIONS: These findings suggest the value 
of measuring health status among stroke patients in addition to assessing 
clinical symptoms as it enables comprehensive evaluation of a patient’s health 
condition.  
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IMPACT OF VELAGLUCERASE ALFA ON QUALITY OF LIFE OF ADULT PATIENTS 
WITH TYPE-I GAUCHER DISEASE  
Elstein D1, Enciu CA2, Fontaine L2, Piwko C3 
1Shaare-Zedek Medical Centre, Jerusalem, Israel, 2Shire HGT (Canada) Inc., Toronto, ON, Canada, 
3PIVINA Consulting Inc., Mississauga, ON, Canada  
OBJECTIVES: Type-1 Gaucher Disease (GD1) causes anemia, thrombocytopenia, 
hepatosplenomegaly, and skeletal pathology. Patients’ health-related quality of 
life (HRQoL) has been shown to be significantly diminished relative to the U.S. 
general population. Velaglucerase alfa is an enzyme replacement therapy (ERT) 
with the most comprehensive clinical trial registration program for an approved 
ERT in GD1 and has been reported as an effective and well-tolerated therapy. 
METHODS: The change in HRQoL, measured using the Short-Form-36 version 2 
(SF-36 v2) in adults at baseline and 1 year in a randomized, double-blinded, 
parallel-group, two-dose Phase III clinical trial of velaglucerase alfa, was 
designated a priori a non-key secondary endpoint. RESULTS: The mean baseline 
(SD) was 42.3 (8.00) and 46.0 (5.90) for the norm-based Physical Component 
Summary (PCS) and 41.7 (12.6) and 48.1 (10.7) for the norm-based Mental 
Component Summary (MCS), respectively, for the 45 U/kg (N=8) and 60 U/kg 
(N=7) treatment arms; the mean U.S. normal population score=50; 1 SD=10). 
Fourteen adult GD1 patients had completed both a baseline and 1 year SF-36 
HRQoL assessment (N=8 receiving 45 U/kg; N=6 receiving 60 U/kg). The respective 
mean change at 1 year [95% CI] for the PCS and MCS was 4.2 [-4.6, 13.0] and 4.1 
[1.0, 7.2] at the low dose and 1.7 [-3.9, 7.2] and 1.2 [-7.9, 10.3] at the high dose. 
Non-significant increases were observed in nearly all of the 8 individual SF-36 v2 
health domains compared to baseline, however, the mean increases, as well as 
the mean increases in the norm-based PCS and MCS summary measures, were 
aligned with the expected achievements of therapeutic goals for HRQoL. 
CONCLUSIONS: In addition to clinical efficacy and safety, velaglucerase alfa 
showed clinically important increases in HRQoL in adults as measured by the SF-
36 v2 within 1 year, however, further studies are needed.  
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CLINICAL AND ECONOMIC EVIDENCE THRESHOLDS FOR ORPHAN DRUGS: ARE 
REQUIREMENTS FOR FAVORABLE HEALTH TECHNOLOGY ASSESSMENT AND 
REIMBURSEMENT ON THE RISE?  
Shih AY1, Duong A1, Tao C2, Ransom JF1, Spinner DS3, White C2, Doyle JJ4, Faulkner EC3 
1Quintiles Consulting, Hawthorne, NY, USA, 2Quintiles Consulting, Cambridge, MA, USA, 
3Quintiles Consulting, Durham, NC, USA, 4Quintiles, Hawthorne, NY, USA  
OBJECTIVES: Orphan drugs are therapies for low prevalence or neglected 
diseases with high unmet need. Many drugs have received orphan status 
globally, and benefited from 5-10 year marketing exclusivity; reduced 
stakeholder evidence requirements with unmet need weighing heavily into 
health technology assessment (HTA) and reimbursement decision-making; and 
largely uncontested pricing. Given tightening health system budgets, the 
proliferation of high priced orphan drugs in the United States (US) and Europe 
(EU) have caused these therapies to come under increased scrutiny from HTA 
agencies and payers to demonstrate value. To gain insight into evolving market 
access requirements, we conducted a multimarket review of orphan drug HTAs 
and reimbursement decisions comparing them to top selling non-orphan drugs 
in the US and EU. METHODS: Global HTAs and coverage decisions for orphan and 
blockbuster drugs were characterized and compared based on health economic, 
clinical and other value-based requirements. An analysis of orphan drug pricing 
was also conducted where pricing was available. RESULTS: More than 20 orphan 
drug HTAs were identified, including those for genetic and central nervous 
system disorders, cancer and cardiovascular disease. HTA agencies and payers 
scrutinized the robustness of clinical evidence and lack of comparator data. 
Cost-effectiveness was also often evaluated, though with relaxed ICER 
thresholds compared to non-orphan drugs. Failure of an orphan drug to meet 
historically accepted evidentiary thresholds have led some evaluators to grant 
conditional reimbursement, with the proviso that further supportive evidence 
must be provided, although outright reimbursement denial has become 
increasingly common. CONCLUSIONS: Once considered “reimbursement-safe” 
for drug developers, to achieve unrestricted reimbursement from payers orphan 
drugs now face higher evidentiary hurdles that are increasingly similar to non-
orphan drugs. New pharmaceuticals intent on achieving optimal market access 
as an orphan drug must factor the evolving requirements for demonstrating 
value into clinical and health economic evidence generation plans.  
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COMPARING ADHERENCE RATES TO DISEASE MODIFYING THERAPIES FOR 
MULTIPLE SCLEROSIS IN COMMERCIAL ENROLLEES AND PART D 
BENEFICIARIES  
Carroll CA 
Teva Pharmaceuticals, Kansas City, MO, USA  
OBJECTIVES: To compare adherence rates, defined as the Medication Possession 
Ratio (MPR), for patients using alternative disease modifying therapies (DMTs)  
to treat multiple sclerosis (MS) that are enrolled in either a commercial 
insurance plan or through the Part D Medicare beneficiary program. METHODS: 
Study patients had >1 pharmacy DMT claim [interferon, glatiramer acetate (GA), 
fingolimod or natalizumab] and were enrolled in either a commercial health  
plan or Part D program between the dates of January 2010 and October 2012  
for patients using interferon, GA and natalizumab and between the dates of 
October 2010 and October 2012 for patients using fingolimod. Mean monthly MPR 
rates were calculated as the percentage of time the patient had access to a 
specific medication. RESULTS: The MPR for 243,330 and 197,784 commercial and 
Part D beneficiaries, respectively, were calculated across the study period. 
Adherence rates for commercial enrollees were similar across disease modifying 
therapies ranging from 75.4% for a once daily oral therapy to 79% for 
natalizumab. However, adherence in Medicare Part D beneficiaries was 
consistently lower than patients enrolled in commercial plans ranging from a 
reduction in MPR of 0.27% for GA to 7.4% in patients taking once daily oral 
fingolimod treatment. CONCLUSIONS: Medicare Part D beneficiaries had lower 
rates of adherence compared to MS patient enrolled in commercial plans which 
could present a unique opportunity for medication management programs 
offered either through pharmaceutical companies, health plans or specialty 
pharmacies.  
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EFFECT OF NEUROLOGIST AMBULATORY VISITS ON USE OF DISEASE-SPECIFIC 
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1University of Washington, Seattle, WA, USA, 2Western University College of Pharmacy, Pomona, 
CA, USA, 3University of New Mexico, Albuquerque, NM, USA  
OBJECTIVES: Neurologists care for chronic neurological illnesses through the use 
of disease-specific pharmacotherapies, but any licensed medical provider can 
prescribe these medications. Therefore, we evaluate effect of neurologist care on 
usage of disease-specific pharmacotherapies for chronic neurological diseases. 
METHODS: Survey respondents from the 2002-2010 Medical Expenditure Panel 
Survey(MEPS), an annual representative dataset of the civilian non-
institutionalized US population, were identified for multiple sclerosis, 
parkinsonism, epilepsy, and dementia. Data collection included prescription 
classes and sub classes (from Cerner Multum) for determining immuno-
modulatory, antiparkinsonian, anticonvulsant, and antidementia medications, 
identified neurologist ambulatory visits, age, illness duration, race, income, 
gender, education, comorbidities, region and year of care. Survey-weighted 
multivariate logistic and ordinary least squares regressions were performed on 
the outcomes of disease specific prescriptions and costs for the calendar year. 
Subgroup analyses were performed for each index condition. RESULTS: A total of 
4948 MEPS respondents (weighted sample: 5.1 million US citizens, 95% CI 4.8m-
5.4m) reported one or more index conditions. Only 27% reported a neurologist 
ambulatory care visit. Neurologist visits were associated with illness duration, 
high school graduate education, insurance coverage, and income. For the group 
seeing a neurologist, the adjusted likelihood of a patient with one of the four 
identified chronic neurological diseases receiving a disease-specific medication 
was substantially greater (OR 2.7, p-value <0.001) and adjusted annual 
expenditures for these medications was a mean of $1780 more (p-value <0.001); 
these estimates varied but were significant for all disease subgroups. 
CONCLUSIONS: Patients are much more likely to receive disease-specific 
pharmacotherapies for chronic neurological conditions when a neurologist is 
involved with their care. Policy makers and pharmaceutical companies should 
consider specialist physician involvement in care as a factor in determining the 
impact of new disease-specific medications.  
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OBJECTIVES: Discrete event simulation (DES) is a tool that allows for the 
organizational domain to be quantified within health technology assessment 
(HTA). This research demonstrates how DES can be used to model improved 
access to care for children with medically refractory epilepsy (MRE). METHODS: 
To develop the DES model from an organizational perspective, a collaborative 
effort is required between the clinical (SickKids) and HTA teams (PATH). We 
completed the analysis in several phases: mapping patient flow, collecting 
resource data, programming the simulation software (ARENA), and estimating 
model inputs. We validated the model for clinical and organizational content 
and goodness-of-fit with the system. Model outputs were flow and wait time (e.g. 
time to surgery). We conducted an analysis of resource capacities on outputs to 
increase access and reduce wait times (30 days to epilepsy monitoring unit 
(EMU), 1.5 years surgery with invasive monitoring and 1 year for surgery 
without). RESULTS: Several iterations were needed to validate patient flow and 
develop confidence in model predictions. Clinical care was described by 4 
modules: EMU (the entry point for diagnostic evaluation), multimodal diagnostic 
assessment, multidisciplinary seizure conference (SC), and surgery. Based on 
analysis of different resource capacities the following increases in resources 
were found to meet the institution’s goals: 2 EMU beds (30 days), 2 invasive 
monitoring surgeries (1.4 years) and 6 non-invasive monitoring surgeries (1 year) 
and limiting the number of repeat SCs to 2. CONCLUSIONS: DES can be used to 
analyze the organizational structure in HTA. Rate limiting factors and efficient 
resource configuration is possible to reach the goal of improving access by 
decreasing wait times. DES can be scaled up from the institution to inform policy 
for the health system overall. By incorporating patient and economic outcomes, 
DES can be used as a platform to bridge the domains of HTA.  
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OBJECTIVES: To calculate and compare the incremental cost-utility ratios for 
standard antiepileptic drug (AED) therapy with and without adjunctive 
lacosamide in patients with uncontrolled partial-onset seizures in Turkey. 
METHODS: A model simulated the treatment pathway of a hypothetical cohort 
of 1000 patients over two years from the third-party payer perspective in Turkey 
in 2012. A decision tree was split into four phases of six months during which 
patients could become seizure free, experience a response to treatment 
(responder defined as ≥50% reduction in seizures), or withdraw due to non-
response. The standard therapy arm included five adjunctive therapies: 
carbamazepine, lamotrigine, levetiracetam, topiramate, and valproate. The 
likelihood of being in a particular health state was estimated from clinical trial 
data. The cost of general practitioner visits, specialist visits, hospitalizations and 
emergency department visits were included. Costs and utility values attached to 
various health states were taken from the published literature. RESULTS: 
Compared with the standard therapy arm, lacosamide adjunctive therapy was 
associated with 6,730 seizures avoided and a gain of 38 quality adjusted life-
years (QALYs). Treatment with lacosamide was associated with an additional 
cost of Turkish Lira (TRY) 205 per seizure avoided and TRY 36,392 per QALY 
gained versus standard therapy without LCM over two years. Results calculated 
for 6-, 12- and 18-month follow-up showed respective incremental cost-utility 
ratios of TRY 38,146, TRY 37,629 and TRY 37,556 and cost per seizure avoided of 
TRY 504, TRY 246 and TRY 219. Sensitivity analysis indicates the base case 
findings are robust, however the model was most sensitive to changes in the 
utility weights. CONCLUSIONS: Lacosamide may be a cost-effective adjunctive 
treatment for patients with uncontrolled partial-onset epilepsy in Turkey. UCB-
funded  
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CLINICAL AND ECONOMIC IMPACT OF FIVE-YEAR ADHERENCE TO DISEASE-
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POPULATION  
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OBJECTIVES: Several published studies have reported the clinical and economic 
impact of adherence to disease-modifying therapies (DMTs) for multiple sclerosis 
(MS), although none have examined the impact of adherence exclusively in 
patients continuously enrolled for five years. The objectives of this study were to 
understand some of the clinical and economic outcomes associated with long-
term adherence/non-adherence to DMTs in MS patients. METHODS: Patients 
who had a medical or pharmacy claim for a DMT between January 1, 2005 to 
December 31, 2005 and who were continuously enrolled until December 31, 2011 
were included in this retrospective cohort study. A total of 664 patients met 
eligibility criteria, and were defined as adherent if they had a medication 
possession ratio (MPR) of greater than 80% in all five years. Propensity Score Bin-
Bootstrapping method was used to control for the variation between the 
adherent and non-adherent groups. Variables used to calculate propensity scores 
were age, gender, comorbidities and severity of disease. RESULTS: Compared 
with the non-adherent group, the adherent group had significantly fewer 
inpatient relapses per year (0.339 vs. 0.215, p<0.01) and had lower annual 
unadjusted medical costs. The non-adherent group had significantly higher 
(p<0.05) adjusted annual medical costs than their matched adherent 
counterparts in all 5 years of the study, except for year 1. From year 1 to year 5, 
adjusted medical costs increased 235% in the non-adherent group compared to 
93% in the adherent group. CONCLUSIONS: MS patients with consistently high 
medication adherence to DMTs over a 5 year period had lower rates of inpatient 
relapse and lower total medical costs than their non-adherent counterparts. 
Given the high cost of DMTs to both payers and patients, it is imperative to 
support and encourage high adherence when using these agents in order to get 
the most value out of the investment in DMTs.  
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TO SODIUM CHANNEL BLOCKERS VERSUS NON-SODIUM CHANNEL  
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OBJECTIVES: Lacosamide is an antiepileptic drug (AED) that enhances sodium 
channel slow inactivation and is approved for adjunctive treatment of partial-
onset seizures in adults. There have been few studies examining patient 
characteristics in patients receiving sodium channel blocking (SCB) versus non-
sodium channel blocking (nSCB) AEDs in addition to lacosamide. The objective of 
this study was to compare patient characteristics and health care utilization in 
nSCB and SCB patients prior to adding lacosamide in a real-world setting. 
METHODS: This was a retrospective database analysis using eligibility, medical 
and pharmacy claims data from a large US health care organization. For 
inclusion, patients had evidence of epilepsy, were continuously enrolled for 6 
months prior to (pre-index) and after (post-index) the 1stpharmacy claim for 
lacosamide (index date), and were receiving at least one other AED (SCB or nSCB) 
for 60 days prior to the index date. If patients were taking ≥1 SCB, they were 
assigned to the SCB group. RESULTS: A total of 720 patients (382 SCB, 338 nSCB) 
met study criteria. Mean age was 35.9 years; 55.7% were female. A total of 62.6% 
of SCB and 30.2% of nSCB patients (p<0.001) were receiving ≥2 AEDs prior to 
adding lacosamide. nSCB patients had higher mean pre-index Quan-Charlson 
Comorbidity (CCI) scores [0.94(SD 1.48) versus 0.49(1.07); p<0.001] and epilepsy-
attributable events [0.56(0.99) versus 0.39(0.84); p=0.015] compared with SCB 
patients. Pre-index health care utilization, including inpatient [0.44(0.85) versus 
0.29(0.68); p=0.006], ER [0.91(2.11) versus 0.60(1.13); p=0.015], physician office 
[10.06(9.86) versus 8.42(9.34); p=0.022] and outpatient visits [5.78(7.95) versus 
4.09(5.78); p=0.001], was higher in nSCB patients compared to SCB patients. 
CONCLUSIONS: Prior to the addition of lacosamide, nSCB patients had greater 
comorbidities, epilepsy-attributable events, and overall health care utilization 
compared to patients using SCB. These findings suggest that nSCB patients had a 
more severe clinical profile compared to SCB patients prior to adding 
lacosamide.  
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OBJECTIVES: During 2007-2011, Multiple Sclerosis (MS) was the only category 
that experienced triple digit growth in sales, leading to a doubling of their sales 
from $3.4 billion in 2007, to $7 billion in 2011. This has led to change in payer 
coverage and utilization of branded MS products. This study was undertaken to 
understand current trends in sales, access, and utilization management for MS 
products in the United States. METHODS: Sales data for MS branded products 
was analyzed using IMS Health 2007-2011 data. Access and utilization 
management trends were analyzed using preferred drug lists and coverage 
policies of top U.S. health plans. To understand new trends in coverage of MS 
products, primary discussions were conducted with pharmacy and medical 
directors to understand new trends in coverage of MS products. RESULTS: More 
than half (approximately 59%) of the branded MS products were covered by 
health plans as non-preferred products or at Tier 3/4. A significant majority (84%) 
of these products were covered with prior authorization or pre-certification 
criteria. Quantity limits were used by 34% of the plans. Use of step therapy or 
progression prescription is not currently common and was found in only 5% of 
the plans. In this sample (n=37), only one plan (<5%) had formulary exclusion for 
an MS product. Payer designated specialty pharmacies are increasingly being 
used by various health plans. Compared to 2007, payer coverage of MS products 
shows significant increase in use of PA (40% in 2007, vs. 84% in 2012). Payers 
express high concern for the rapidly growing MS category and report use of more 
utilization management approaches to control spending. CONCLUSIONS: MS 
products are facing more aggressive utilization management. Patient access for 
new MS therapies could be limited due to non-preferred status, high co-pay, or 
strict PA criteria.  
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OBJECTIVES: To examine the gene expression alterations in rat’s brain, treated 
by non-ionizing electromagnetic radiation from 900MHz-GSM mobile phone is 
main aim of this study. METHODS: We investigated whether an exposure of 
GSM-900 MHz irradiation from the mobile phone (3hours/day up to 28 days) 
could lead to the modulation of gene expression pattern in the rat brain. All rats 
were habitualised for one week prior to start the experiment in well designed 
circular mobile phone exposure (CCPE) cage. CCPE cage was specially designed 
for EMR exposure by mobile phone on the rats in the natural environment and it 
placed inside the exposure room where other electric appliances were not 
installed. In the cage, mobile phone was placed in the center and rats were 
